Literature DB >> 26575972

Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease.

Subramaniam Pennathur1,2, Anuradha Vivekanandan-Giri1, Morgan L Locy3, Tejaswini Kulkarni3, Degui Zhi4, Lixia Zeng1, Jaeman Byun1, Joao A de Andrade3, Victor J Thannickal3.   

Abstract

RATIONALE: Interstitial lung diseases (ILDs) are associated with oxidative stress. Plasma biomarkers that are directly linked to oxidative stress responses in this disease have not been identified. Stable oxidation products of tyrosine residues in proteins may reflect the oxidative microenvironment in the lung or a systemic inflammatory state.
OBJECTIVES: To determine if levels of protein tyrosine oxidation are elevated in plasma of patients with ILD compared with an age- and sex-matched healthy control cohort.
METHODS: Three tyrosine oxidation products (3-chlorotyrosine, 3-nitrotyrosine, and o,o'-dityrosine) were quantified by tandem mass spectrometry in cellular models, a mouse model of injury-induced fibrosis, and in plasma of healthy control subjects and patients with ILD (n = 42 in each group).
MEASUREMENTS AND MAIN RESULTS: Plasma levels of 3-chlorotyrosine, 3-nitrotyrosine, and o,o'-dityrosine were markedly elevated in patients with ILD compared with control subjects with receiver operating characteristic curves separating these groups of 0.872, 0.893, and 0.997, respectively. In a murine model of lung fibrosis, levels of all three oxidative tyrosine modifications were increased in plasma and lung tissue. Cellular models support a critical role for a heme peroxidase and enzymatic sources of reactive oxygen species in the generation of these oxidized products.
CONCLUSIONS: We demonstrate an increase in oxidized tyrosine moieties within proteins in the circulating plasma of patients with ILD. These data support the potential for development of oxidative stress-related biomarkers in early diagnosis, prognostication, and/or in evaluating responsiveness to emerging therapies for ILD.

Entities:  

Keywords:  chlorotyrosine; dityrosine; mass spectrometry; nitrotyrosine; oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 26575972      PMCID: PMC4849179          DOI: 10.1164/rccm.201505-0992OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  45 in total

1.  o-Tyrosine and dityrosine concentrations in oxidized proteins and lens proteins with age.

Authors:  T G Huggins; M W Staton; D G Dyer; N J Detorie; M D Walla; J W Baynes; S R Thorpe
Journal:  Ann N Y Acad Sci       Date:  1992-11-21       Impact factor: 5.691

2.  Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model.

Authors:  Hanzhong Liu; Peter Drew; Yanping Cheng; Gary A Visner
Journal:  J Thorac Cardiovasc Surg       Date:  2005-09       Impact factor: 5.209

3.  Myeloperoxidase generates 5-chlorouracil in human atherosclerotic tissue: a potential pathway for somatic mutagenesis by macrophages.

Authors:  Junko Takeshita; Jaeman Byun; Thomas Q Nhan; David K Pritchard; Subramaniam Pennathur; Steven M Schwartz; Alan Chait; Jay W Heinecke
Journal:  J Biol Chem       Date:  2005-12-01       Impact factor: 5.157

4.  Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.

Authors:  Atsushi Hirano; Arihiko Kanehiro; Katsuichiro Ono; Wataru Ito; Akio Yoshida; Chiharu Okada; Hiromi Nakashima; Yasushi Tanimoto; Mikio Kataoka; Erwin W Gelfand; Mitsune Tanimoto
Journal:  Am J Respir Cell Mol Biol       Date:  2006-05-04       Impact factor: 6.914

5.  Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts.

Authors:  Meghna Waghray; Zongbin Cui; Jeffrey C Horowitz; Indhu M Subramanian; Fernando J Martinez; Galen B Toews; Victor J Thannickal
Journal:  FASEB J       Date:  2005-02-16       Impact factor: 5.191

Review 6.  Emerging drugs for idiopathic pulmonary fibrosis.

Authors:  Victor J Thannickal; Kevin R Flaherty; Robert C Hyzy; Joseph P Lynch
Journal:  Expert Opin Emerg Drugs       Date:  2005-11       Impact factor: 4.191

Review 7.  Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy.

Authors:  Vuokko L Kinnula; Cheryl L Fattman; Roderick J Tan; Tim D Oury
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

8.  Tyrosine phosphorylation regulates H2O2 production in lung fibroblasts stimulated by transforming growth factor beta1.

Authors:  V J Thannickal; K D Aldweib; B L Fanburg
Journal:  J Biol Chem       Date:  1998-09-04       Impact factor: 5.157

9.  Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr.

Authors:  Marcus Ståhlman; Pia Davidsson; Ida Kanmert; Birgitta Rosengren; Jan Borén; Björn Fagerberg; Germán Camejo
Journal:  J Lipid Res       Date:  2007-11-18       Impact factor: 5.922

10.  Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis.

Authors:  Akihito Yokoyama; Keiichi Kondo; Masamitsu Nakajima; Toshiharu Matsushima; Toru Takahashi; Masaharu Nishimura; Masashi Bando; Yukihiko Sugiyama; Yoshitaka Totani; Takeshi Ishizaki; Hidenori Ichiyasu; Moritaka Suga; Hironobu Hamada; Nobuoki Kohno
Journal:  Respirology       Date:  2006-03       Impact factor: 6.424

View more
  15 in total

1.  Update in Interstitial Lung Disease 2016.

Authors:  Athol U Wells; Toby M Maher
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

2.  Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.

Authors:  Farsad Afshinnia; Lixia Zeng; Jaeman Byun; Crystal A Gadegbeku; Maria Chiara Magnone; Carl Whatling; Barbara Valastro; Matthias Kretzler; Subramaniam Pennathur
Journal:  Am J Nephrol       Date:  2017-07-01       Impact factor: 3.754

3.  Structured lifestyle intervention in patients with the metabolic syndrome mitigates oxidative stress but fails to improve measures of cardiovascular autonomic neuropathy.

Authors:  Subramaniam Pennathur; Mamta Jaiswal; Anuradha Vivekanandan-Giri; Elizabeth A White; Lynn Ang; David M Raffel; Melvyn Rubenfire; Rodica Pop-Busui
Journal:  J Diabetes Complications       Date:  2017-05-02       Impact factor: 2.852

4.  Is personalized medicine a realistic goal in idiopathic pulmonary fibrosis?

Authors:  Victor J Thannickal; Veena B Antony
Journal:  Expert Rev Respir Med       Date:  2018-04-19       Impact factor: 3.772

Review 5.  Mechanisms for the Resolution of Organ Fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Physiology (Bethesda)       Date:  2019-01-01

6.  Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosis.

Authors:  Lixia Zeng; Anna V Mathew; Jaeman Byun; Kevin B Atkins; Frank C Brosius; Subramaniam Pennathur
Journal:  J Biol Chem       Date:  2018-03-26       Impact factor: 5.157

Review 7.  Redox mechanisms in age-related lung fibrosis.

Authors:  Ashish Kurundkar; Victor J Thannickal
Journal:  Redox Biol       Date:  2016-06-25       Impact factor: 11.799

Review 8.  Regulation of Chemokine Function: The Roles of GAG-Binding and Post-Translational Nitration.

Authors:  Sarah Thompson; Beatriz Martínez-Burgo; Krishna Mohan Sepuru; Krishna Rajarathnam; John A Kirby; Neil S Sheerin; Simi Ali
Journal:  Int J Mol Sci       Date:  2017-08-03       Impact factor: 5.923

9.  Oxidative cross-linking of fibronectin confers protease resistance and inhibits cellular migration.

Authors:  Morgan L Locy; Sunad Rangarajan; Sufen Yang; Mark R Johnson; Karen Bernard; Ashish Kurundkar; Nathaniel B Bone; Jaroslaw W Zmijewski; Jaeman Byun; Subramaniam Pennathur; Yong Zhou; Victor J Thannickal
Journal:  Sci Signal       Date:  2020-08-11       Impact factor: 9.517

Review 10.  Lung extracellular matrix and redox regulation.

Authors:  Walter H Watson; Jeffrey D Ritzenthaler; Jesse Roman
Journal:  Redox Biol       Date:  2016-02-18       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.